F.W. Wit

Latest

• Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response
• Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy
• Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz
• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
• Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy